BioDelivery Sciences Appoints Jeffrey A. Bailey to its Board of Directors
09 Mars 2020 - 1:00PM
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly
growing specialty pharmaceutical company dedicated to patients
living with serious and complex chronic conditions, today announced
that it has appointed Jeffrey A. Bailey to its Board of Directors.
Mr. Bailey brings more than 30 years of leadership experience
building and leading high-quality pharmaceutical businesses across
a diverse variety of important disciplines relevant to the
continued growth and evolution of BDSI. He has an extensive
track record of creating significant shareholder value both
organically and through business development pathways.
“I am very excited to have Jeff join our board
of directors,” stated Peter Greenleaf, Chairman of BDSI. “His
extensive experience in both running commercial operations and
driving value through corporate transactions will further expand
our company’s leadership as we continue driving our growth momentum
into the future.”
“This is a wonderful time to be joining the
board of BDSI,” stated Jeff Bailey. “The Company has
experienced a very successful transition over the last few years
and is well positioned to further capitalize on its success.
I look forward to working as a member of the board to help the
Company accomplish its ambitions.”
Jeff joins the BDSI board bringing diverse
leadership experiences in commercial and supply chain management
during a 20+ year career at Johnson & Johnson/Janssen
Pharmaceutica as well as during a tenure as an Operating Unit
President at Novartis Pharmaceuticals. He also has extensive
business development and transactional expertise that includes
officer roles during King Pharmaceuticals’ acquisition by Pfizer,
Fougera Pharmaceuticals’ acquisition by Novartis, and as Chairman
and CEO during Neurovance’s acquisition by Otsuka.
Additionally, Mr. Bailey served as President and CEO of Lantheus
Medical Imaging, Inc, taking the company public in 2015.
Currently, Mr. Bailey serves as Chairman of
Aileron Therapeutics since March 2018 and as a Board Member of
Madison Vaccines, a privately held biopharmaceutical company, since
October 2017. Since January 2018, Mr. Bailey has served
as CEO and Director of IlluminOss Medical, Inc.
Mr. Bailey received a B.S. from Rutgers University.
About BioDelivery Sciences
International, Inc.
BioDelivery Sciences International, Inc.
(NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical
company dedicated to patients living with chronic conditions. BDSI
has built a portfolio of products that includes utilizing its novel
and proprietary BioErodible MucoAdhesive (BEMA®) technology to
develop and commercialize, either on its own or in partnership with
third parties, new applications of proven therapies aimed at
addressing important unmet medical needs. BDSI's marketed products
address serious and debilitating conditions, including chronic
pain, opioid dependence, and opioid-induced constipation.
Cautionary Note on Forward-Looking
Statements
This press release and any statements of
employees, representatives, and partners of BDSI related thereto
contain, or may contain, among other things, certain
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve significant risks and uncertainties. Such
statements may include, without limitation, statements with respect
to the BDSI’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential” or similar expressions. These statements are based upon
the current beliefs and expectations of the BDSI’s management and
are subject to significant risks and uncertainties, including those
detailed in the BDSI’s filings with the Securities and Exchange
Commission. Actual results may differ materially from those set
forth or implied in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the BDSI’s control) including those set forth in our
2018 annual report on Form 10-K filed with the US Securities and
Exchange Commission and subsequent filings. BDSI undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
© 2020 BioDelivery Sciences International, Inc.
All rights reserved.
Contact:
Tirth T. PatelDirector of Investor
Relationstpatel@bdsi.com(919) 582-0294
BioDelivery Sciences (NASDAQ:BDSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
BioDelivery Sciences (NASDAQ:BDSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024